Fisetin for Muscle Preservation and Frailty: The Evidence (2026)

Does fisetin actually help preserve muscle and prevent frailty?

Fisetin's case for muscle preservation is the strongest recent preclinical case in the entire fisetin field. A 2025 mouse study found that intermittent fisetin dosing improved frailty scores and grip strength in aged mice, to a similar extent as two established senolytic approaches [1]. That's a genuinely unusual result for a natural compound.

Multiple human trials now test related questions in frailty, sarcopenia, walking performance and cancer survivorship. Most remain ongoing, and the available human evidence has not established a muscle-preservation benefit. For the full context, see our complete clinician's guide.

What is proven for muscle: mice versus people

The 2025 mouse study supports a preclinical research hypothesis, not a clinical promise. Human research includes ongoing or recently completed condition-specific fisetin trials with different regimens and endpoints; results cannot be inferred from their registration or rationale. For interpretation of the latest physical-function trial pipeline, see our full benefits evidence map and human pulse schedules.

Readers comparing longevity ingredients should also see fisetin versus urolithin A: the latter's July 2026 review included five human muscle-related RCTs but its pooled walking result was statistically inconclusive. These are different interventions and study populations, not evidence that their combination benefits frailty.

What did the 2025 Murray study actually show?

The design

Researchers compared old mice (27–29 months, a genuinely advanced age for a mouse) against young mice (6–8 months), testing intermittent oral fisetin against two other well-established ways of clearing senescent cells: a genetic model that allows selective clearance of p16-positive senescent cells with a triggering drug, and ABT-263, a synthetic pharmaceutical senolytic used in cancer research [1].

The endpoints — and what wasn't measured

The study measured two functional outcomes: a validated mouse frailty index score, and grip strength. It also ran RNA sequencing on quadriceps muscle to look at gene-expression changes linked to cellular senescence, finding reduced expression of senescence-related genes including Cdkn1a (p21) and Ddit4 in fisetin-treated mice.

Worth being precise about: this study did not include gait-speed testing, rotarod testing, or histological staining of muscle tissue for senescent cells — its own discussion section notes that histological confirmation is something future work should add. The evidence here is frailty score, grip strength, and gene expression, not a full physical-performance battery.

The result

Fisetin improved frailty scores and grip strength to a similar degree as both the genetic senescent-cell clearance model and ABT-263. Three very different interventions — a natural flavonoid, a genetic model, and a pharmaceutical senolytic — produced a comparable functional outcome. Most natural compounds show meaningfully smaller effects than their pharmaceutical comparators, which is what makes this result worth taking seriously.

Why would clearing senescent cells help muscle at all?

Sarcopenia — the age-related loss of muscle mass, strength, and physical performance — is a major driver of frailty and disability in older adults, and its formal clinical definition was updated by a European consensus panel in 2019 [2]. Its biology is multifactorial: reduced protein synthesis, mitochondrial dysfunction, and neuromuscular junction decline all contribute.

Senescent cells in skeletal muscle secrete inflammatory SASP factors that impair the function of satellite cells — the muscle stem cells responsible for repair and regeneration. This creates a self-reinforcing cycle: senescent cells damage nearby tissue's regenerative capacity, which accelerates further senescent-cell build-up. Clearing senescent cells can break this cycle, which is why senolytic interventions have repeatedly shown muscle-function benefits in preclinical models. Xu and colleagues established this general principle in mice using the D+Q senolytic combination [3]; Murray 2025 extended it to fisetin specifically [1].

What is the human trial pipeline testing this?

The human pipeline is now broader than the three studies previously highlighted.

Study	Population	Functional question	Status / interpretation
AFFIRM	Older women with frailty/gait disturbance	Walking and frailty-related outcomes	Ongoing; no results
PROFFi	Breast-cancer survivors	Fisetin, exercise and their combination for frailty/physical function	Recruiting; factorial design
TROFFi	Postmenopausal breast-cancer survivors after chemotherapy	6-minute walk performance after repeated 3-day fisetin cycles	Recruiting; no results
REVITALiSE	Adults ≥65 with sarcopenia	4-metre walk speed, grip strength, activity and muscle biopsy outcomes	Recruiting; direct fisetin-vs-usual-care subtrial
SEN-SURVIVORS	Adult survivors of childhood cancer	Walking speed, frailty and senescence markers	Active; fisetin compared with D+Q
FIRST	Peripheral artery disease	6-minute walk distance plus tissue/blood senescence markers	Recruiting; mobility endpoint in a vascular population
Fisetin HIGH	Healthy volunteers and older adults with multimorbidity	PK, safety, frailty/physical function and senescence biomarkers	Ongoing; no results

The most directly relevant new study for sarcopenia is REVITALiSE, because it randomizes older adults to fisetin or usual care and includes functional mobility plus muscle-biopsy outcomes. [10]

This pipeline is encouraging as research activity, but it is not yet positive human efficacy evidence.

Is there any safety data for fisetin in older, frailer adults?

Fisetin's broader senolytic mechanism was established by Yousefzadeh and colleagues, who showed it selectively clears senescent human cells [7]. A separate senolytic pilot trial using the dasatinib-plus-quercetin combination (not fisetin) in patients with idiopathic pulmonary fibrosis reported an acceptable tolerability profile for pulsed senolytic dosing in a frail, older population [8] — relevant context for the general pulsed-senolytic approach, though it doesn't establish fisetin-specific safety data in frail older adults. That specific question is one of the things the Fisetin HIGH trial is designed to answer directly.

Does fisetin's bioavailability affect any of this?

Oral fisetin exposure is formulation-dependent. The small human crossover study reports dose-adjusted blood concentrations, not measurements of fisetin or metabolites inside human skeletal muscle [9]. Laboratory senolytic concentrations are not validated human muscle-treatment thresholds. It remains unknown whether any studied fisetin regimen reduces muscle senescence or improves clinically meaningful frailty outcomes.

What should you actually do?

For muscle preservation and frailty prevention, established interventions remain the foundation: progressive resistance exercise, adequate protein and energy intake, and evaluation of reversible contributors to weakness or weight loss.

Fisetin remains experimental for this purpose. Human studies use several different schedules, including two-day pulses, three-day pulses and weight-banded three-day courses every two weeks. No regimen has been shown to preserve muscle or prevent frailty in a completed, adequately powered human trial.

That means the correct practical conclusion is not to choose whichever trial schedule looks most aggressive. It is to treat fisetin as an unproven adjunct while the direct sarcopenia and frailty trials mature.

What we still don't know

Whether the Murray 2025 mouse result translates to humans remains unresolved; AFFIRM, PROFFi, TROFFi, REVITALiSE and related functional trials address different parts of that question.

Whether the pulsed protocol produces cumulative benefit over years, or hits a ceiling as resistant senescent-cell populations expand.

Whether combining fisetin with resistance training is additive — plausible based on mechanism, but untested in humans.

Whether specific groups — by sex, baseline frailty, or sarcopenic status — respond differently. Not directly tested.

Whether fisetin's muscle-preservation effect, if it exists in humans, is meaningful in people who are already frail, or requires earlier intervention.

Bottom line

Muscle preservation and frailty prevention is the strongest recent preclinical case in the fisetin field — a 2025 mouse study found effects comparable to two established senolytic approaches, measured by frailty score and grip strength. Multiple human trials now test frailty, walking performance, sarcopenia and senescence-related biology, but direct clinical efficacy remains unproven. Resistance exercise and adequate nutrition retain much stronger evidence. Fisetin should be treated as experimental rather than as a trial-validated muscle-preservation protocol. When AFFIRM publishes, this article will be among the first revised. For the full context, see our complete clinician's guide and dedicated senolytic article.